K-Ras siRNA (h) from Santa Cruz Biotechnology, Inc.

Product Specs
ItemK-Ras siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-35731
Gene Namev-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Quantity10 µM
Specieshuman
NCBI Full Gene NameKRAS proto-oncogene, GTPase
NCBI Gene Aliases'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2
TypesiRNA/dsRNA

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancerExperimental & Molecular MedicineSeptember 12, 2025Dong Hoon Shin, Minyoung Choi, Chungyong Han, Sang Soo KimJNK1-GFP (#86830) plasmids were purchased from Addgene. Small interfering RNAs (siRNAs), including siKRAS (sc-35731 and sc-43874), siSIRT1 (sc-40986) and siSmad2/3 (sc-37238) and antibodies including SIRT1 (sc-15454),

(2) Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell LineJournal of gastrointestinal cancerSeptember 1, 2022Kamran S, Seyedrezazadeh E, Shanehbandi D, Asadi M, Zafari V, Shekari N, Namvar L, Zarredar H.

(3) Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer CellsMolecular cancer research : MCRApril 1, 2022Zhang S, Zhou L, El-Deiry WS.(catalog no. 6436) were purchased from Cell Signaling Technology. siRNA#1 targeting Ras (catalog no. sc-35731), siRNA targeting C-Raf (catalog no. sc-29462), and siRNAs targeting B-Raf (catalog no. sc-36368) were

(4) Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1OncogeneJanuary 1, 2022Shin DH, Kim SH, Choi M, Bae YK, Han C, Choi BK, Kim SS, Han JY.

(5) Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung CancerMolecular cancer research : MCRAugust 1, 2021Liu S, Gandler HI, Tošić I, Ye DQ, Giaccone ZT, Frank DA.ng/ml. 5-azacytidine (Sigma) was used at concentration of 1 μM. siRNAs targeting either human KRAS (sc-35731) or GLUT1 (sc-35493) were obtained from Santa Cruz. siRNAs targeting human STAT3 (D-003544-03-0020)

(6) CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancerBritish journal of cancerSeptember 1, 2020Lin JX, Yoon C, Li P, Ryeom SW, Cho SJ, Zheng CH, Xie JW, Wang JB, Lu J, Chen QY, et al.

(7) The RAS-interacting chaperone UNC119 drives the RASSF6-MDM2-p53 axis and antagonizes RAS-mediated malignant transformationThe Journal of biological chemistryAugust 7, 2020Shimizu T, Nakamura T, Inaba H, Iwasa H, Maruyama J, Arimoto-Matsuzaki K, Nakata T, Nishina H, Hata Y.

(8) The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung CancerCancersMay 28, 2020Lee SH, Jeon Y, Kang JH, Jang H, Lee H, Kim SY.H00003845-M01, 1:1000) was purchased from Abnova (Taipei, Taiwan). Control siRNA (sc-37007) and KRAS siRNA (Cat. Sc-35731) were purchased from Santa Cruz Biotechnology. Hs.KRAS4B (Cat. 83129) and Hs.KRAS4B G12D (Cat. 83131)

(9) Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulationBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapieFebruary 1, 2020Petanidis S, Domvri K, Porpodis K, Anestakis D, Freitag L, Hohenforst-Schmidt W, Tsavlis D, Zarogoulidis K.

(10) CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric TumorigenesisMolecular cancer research : MCRNovember 1, 2019Choi SI, Yoon C, Park MR, Lee D, Kook MC, Lin JX, Kang JH, Ashktorab H, Smoot DT, Yoon SS, et al.

(11) KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes MetastasisMolecular cancer research : MCRSeptember 1, 2019Yoon C, Till J, Cho SJ, Chang KK, Lin JX, Huang CM, Ryeom S, Yoon SS.

(12) Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitorJournal of cellular biochemistryJune 1, 2019Zarredar H, Pashapour S, Farajnia S, Ansarin K, Baradaran B, Ahmadzadeh V, Safari F.

(13) Small Molecule KRAS Agonist for Mutant KRAS Cancer TherapyMolecular cancerApril 10, 2019Xu K, Park D, Magis AT, Zhang J, Zhou W, Sica GL, Ramalingam SS, Curran WJ, Deng X.

(14) KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugsJournal of controlled release : official journal of the Controlled Release SocietyFebruary 28, 2019Liu H, Sun M, Liu Z, Kong C, Kong W, Ye J, Gong J, Huang DCS, Qian F.

(15) Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitroJournal of cellular physiologyFebruary 1, 2019Zarredar H, Pashapour S, Ansarin K, Khalili M, Baghban R, Farajnia S.

(16) Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine modelJournal of cellular and molecular medicineJune 1, 2018Hsu PC, Miao J, Huang Z, Yang YL, Xu Z, You J, Dai Y, Yeh CC, Chan G, Liu S, et al.

(17) Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cellsInternational journal of oncologyMay 1, 2018Du Z, Song X, Yan F, Wang J, Zhao Y, Liu S.control. siRNA targeting KRAS proto-oncogene GTPase (KRAS) and the negative control siRNA (cat. nos. sc-35731 and sc-37007, respectively) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Cells

(18) Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic CancerCancersMarch 29, 2018Manegold P, Lai KKY, Wu Y, Teo JL, Lenz HJ, Genyk YS, Pandol SJ, Wu K, Lin DP, Chen Y, et al.

(19) KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory LoopCancer researchMarch 15, 2018Fujimura K, Wang H, Watson F, Klemke RL.lentiviral particles targeting Kras has been previously described and was purchased from Santa Cruz (sc-35731)[15]. The siRNA targeting eIF5A1 was purchased from Thermo (M-015739–00–0005), eIF5A2 and PEAK1 siRNA

(20) miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK PathwayCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacologyJanuary 1, 2018Sun W, Ping W, Tian Y, Zou W, Liu J, Zu Y.

Be the First to Write a Review!

K-Ras siRNA (h)

K-Ras siRNA (h) from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (37)

Reviews

K-Ras siRNA (h) from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map